Merck & Co. (>> Merck & Co., Inc.) has struck a global collaboration agreement for the development and commercialization of Pfizer’s potential treatment for Type 2 diabetes.
The agreement excludes Japan and pertains to ertugliflozin, an investigational oral sodium glucose cotransporter inhibitor. The firms noted ertugliflozin is Phase 3 ready, with trials expected to begin later this year.
“Through this collaboration, we believe we can build on Merck’s leadership position in diabetes care with the introduction of ertugliflozin, an innovative SGLT2 inhibitor discovered by Pfizer scientists,” said John Young, president and general manager of Pfizer Primary Care.
Merck and Pfizer will collaborate on the clinical development and commercialization of ertugliflozin and ertugliflozin-containing fixed-dose combinations with metformin and Januvia tablets. Merck will continue to retain the rights to its existing portfolio of sitagliptin-containing products.
Tapp here to read more about the merger between Merck and Pfizer.
Have type 2 diabetes? Share how you feel about this story.TAPP to read more.
Please contact firstname.lastname@example.org with any DMCA or other intellectual property concerns.